


Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (**EV 291841785 US**) in an envelope addressed to:
Mail Stop: Patent Applications
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this **26th** day of **March** 2004.

s/ 
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Stuart GREEN, et al.

Group Art Unit: To be Assigned

Serial No.:
To be Assigned, Divisional of 10/339,087

Examiner: To be Assigned

Filed: Herewith

**For: TRIAZOLE DERIVATIVES USEFUL IN
THERAPY**

Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☒ This application is a continuation, divisional or continuation-in-part of Serial No. 10/339,087. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: March 26, 2004



Elsa Djuardi
Attorney For Applicants
Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-**extension**
Fax: (858) 678-8233

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Stuart Green, et al.

Examiner:

Not Yet Assigned

SERIAL NO. Not Yet Assigned

Art Unit:

FILED: Herewith

Not Yet Assigned

FOR: Triazole Derivatives Useful in
Thearpy

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant herein makes available to the Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: July 28, 1995


James T. Jones
Attorney for Applicants
Reg. No.30,561

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-4903

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> Page 1 of 1										ATTY. DOCKET NO. PC9400AJTJ			SERIAL NO.		
										APPLICANT Stuart Green, et al.					
										FILING DATE Hereewith			GROUP		

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4	9	5	2	2	3	2	8/28/90	Cuomo et al.	A01N	43/653			

FOREIGN PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	YES	NO												
	0	4	7	2	3	9	2A2	19/08/91	EP	C07D	249/08			
	2	0	9	9	8	1	8A	22/04/82	GB	C07D	249/08			
	0	4	4	0	3	7	2A1	24/01/91	EP	C07D	403/06			
	9	5	2	2	9	7	3	31/08/95	WO	A61K	31/41			
	0	1	0	6	8	0	7A1	10/10/83	EP	C07F	9/65			
	0	5	7	6	2	0	1A2	16/6/93	EP	C07D	249/08			
	0	4	1	3	6	7	4A2	13/08/90	EP	C07D	9/59			
	0	6	6	7	3	4	6A2	03/02/95	EP	C07D	417/06			
	9	7	0	1	5	5	2	16/01/97	WO	C07D	403/10			
	0	5	6	7	9	8	2A1	3/11/93	EP	C07D	249/12			

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>														
EXAMINER INITIAL	63-Pharmaceuticals, Vol. 119, 1993, page 525													
	Maurin, et al. Int. J. Pharm., 1993, Vol. 94, pp. 11-14													

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<i>Notice of References Cited</i>			Application No. 11/335,689		Applicant(s) C. J. ...	
			Examiner H. J. ...		Group Art Unit 1625	
Page 1 of 1						
U.S. PATENT DOCUMENTS						
*	DOCUMENT NO.	DATE	NAME		CLASS	SUBCLASS
A	5,278,175	1/1994	T. R. ...		514	340
B	5,767,977	1/1998	H. ...		514	85
C						
D						
E						
F						
G						
H						
I						
J						
K						
L						
M						
FOREIGN PATENT DOCUMENTS						
*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						
NON-PATENT DOCUMENTS						
*	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)					DATE
U						
V						
W						
X						

* A copy of this reference is not being furnished with this Office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)